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Abstract 
Aims: The aim of this study is to assess concordance 
with the British Society of Rheumatology (BSR) 2010 
recommendations on the use of biologic therapy in 
Rheumatoid Arthritis (RA). The Disease Activity Score in 
28 joints (DAS 28), a composite numerical score is 
included in these recommendations to assess disease 
activity and response to treatment. 
Methods: Clinical notes of fifty patients who were 
commenced on biologic treatment between March 2010 
and June 2011 were reviewed for documentation of DAS 
28 scores at baseline, after approximately 6 months of 
commencement of treatment and at approximately 6 
monthly intervals during treatment.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results: Twenty two patients were eligible for 
this audit. Of these patients only half had a DAS 28 
score performed prior to starting treatment, four 
patients had the score performed within 3-9 months of 
commencement of therapy and only 2 patients had 
continuous scores performed at six monthly intervals 
during treatment.       
Conclusions: This audit shows that we are not 
adhering to the BSR recommendations. In order to 
improve our adherence we plan to train all staff in 
contact with patients on biologic treatment to perform 
DAS 28 scores and have a DAS 28 calculator readily 
available at out patients. A proforma is being 
developed for patients on biologic therapy to ensure 
that DAS 28 scores are performed at baseline and 
during treatment.  
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Introduction 
Rheumatoid arthritis (RA), a systemic disease, is 
characterized by a chronic inflammatory reaction in 
the synovium of joints and is associated with 
degeneration of cartilage and erosion of juxta-articular 
bone. Many pro-inflammatory cytokines including 
tumour necrosis factor-alpha, chemokines, and growth 
factors are expressed in diseased joints.
1
 Extra-
articular features and systemic symptoms can also 
commonly occur.  
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RA has a worldwide distribution and an estimated 
prevalence of 1-2%. For many years non-biologic Disease 
Modifying Anti-Rheumatic Drugs (DMARDs) such as 
methotrexate, sulphasalazine, leflunomide and 
hydroxychloroquine have been used singly or in 
combination to manage the disease. DMARD treatment 
has undergone dramatic changes over the past decade and 
biologic DMARD therapy has revolutionized the 
management of the disease.
2
 The development of biologic 
DMARDS followed an increased understanding in the 
pathogenesis of inflammatory arthritis with the 
identification of cytokines which are key players in the 
inflammatory process. Their target is highly specific with 
the mode of action easier to elucidate than with traditional 
DMARDs. 
Biologic drugs have allowed rheumatologists to 
satisfactorily control RA resistant to conventional 
DMARDs. All the biologic DMARDs are very expensive 
and their unrestricted use would be unaffordable.
3
 Thus 
judicious use and review of such treatment is imperative to 
identify partial or non responders. 
The BSR working party on biologic therapies started 
to work on guidelines to produce recommendations on the 
appropriate use of these therapies in RA in 2007. The three 
recommendations which were finalized and published in 
March 2010
 
are used in this audit.
4
 They include eligibility 
criteria for biologic treatment and continuous monitoring 
of response to treatment using a validated score, the 
Disease Activity Score of 28 joints (DAS 28).
 
DAS 28 is a composite, numerical score combining 
several discrete measures of RA activity into a single 
grading of disease severity. It comprises objective (ESR), 
subjective (patient well being) and semi-objective (joint 
swelling and joint tenderness) criteria in 28 joints 
(including shoulder, elbow, wrist, metacarpophalangeal 
and proximal interphalagneal and knees) commonly 
involved in RA (Table 1).  
 
Table 1: How to calculate DAS28 
Variables Result 
Number of swollen (0-28)  
Number of tender joints (0-28)  
ESR (or CRP)  
Visual analogue scale (VAS) disease activity (0-
100mm) 
 
 
 
 
 
How to calculate the DAS 28 score 
1. Collect the data for the number of swollen and 
the number of tender joints, the ESR (or CRP) 
and the VAS for disease activity. 
2. Use the equation below 
DAS28=0.56*√(TENDER 
JOINTS)+0.28*√(SWOLLEN 
JOINTS)+0.70*LN(ESR/CRP)+0.014*VAS 
 
It is used to assess disease activity and monitor 
response to treatment with DMARDs. The European 
League Against Rheumatism (EULAR), published 
response criteria suggesting that biologics should be 
stopped if there is less than 20% improvement in DAS 
28 at 3-6 months.
5 
These response criteria were 
utilized by the BSR in the recommendations. 
The above guidelines were chosen because they 
are recent, evidence based and comprehensive. If we 
are not adhering to the above recommendations we 
propose to implement change in our department to be 
consistent and give to our patients evidence based 
care. 
The primary aim of this audit was to assess 
concordance of departmental management with BSR 
2010 recommendations on biologic therapy use in RA. 
Secondary aims were auditing of the use of the DAS 
28 prior to starting biologic therapy and its use to 
measure the response to treatment with biologic 
agents. 
 
Patients and Methods 
Patients 
The demographic data of all patients with RA 
commenced on an anti-TNF agent and recorded in the 
database of the pharmacy department at Mater Dei 
Hospital from March 2010 to June 2011 were 
collected. The records held by the specialist nurse on 
patients receiving biologic therapy were also reviewed 
to ascertain completeness of recruitment of all the 
patients.  
Methods 
This is a retrospective audit. The case notes of the 
patients were reviewed to extract the following 
information: 
1. DAS 28 score recorded at baseline (before 
starting treatment with anti TNF therapy). 
2. Whether the DAS 28 score at baseline was 
appropriate for commencement of biologic 
therapy (i.e. ≥3.2). 
3. Use of non biologic DMARD prior to starting anti 
–TNF. 
4. DAS 28 scores recorded after commencement of 
treatment.  
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5. Achievement of an adequate EULAR response after 3 
to 9 months of starting anti –TNF (≥20% 
improvement in DAS 28) 
6. Regular recording of DAS 28 scores during treatment. 
Statistics 
Non parametric statistics were used throughout the 
analysis 
 
Results 
Fifty patients were commenced on biologics from 
March 2010 to June 2011 (16 months). 
of these patients, 28 (56%) suffered from RA, diagnosed 
according to the 1987 American College of Rheumatology 
Criteria. These latter patients were included in the study. 
Twenty two (44%) patients were excluded from the study. 
These included those patients who were treated with 
biologic treatment for conditions other than RA such as 
Ankylosing Spondylitis, Psoriatic Arthritis and Juvenile 
Idiopathic Arthritis and those patients who had incomplete 
data recorded in the hospital notes because the patients 
were also visiting their rheumatologist in clinics outside 
the hospital. 
Four patients did not start treatment, despite having a 
biologic treatment prescribed. These were patients who 
after appropriate counselling about potential side effects of 
anti–TNF therapy refused the treatment. 
Two further patients were excluded from the study 
because they were already on biologic treatment prior to 
settling in Malta.  
This left us with 22 patients eligible for the audit. 
  
 
 
 
 
 
 
 
 
 
 
Figure 1: Number of patients who suffered from RA and 
were enrolled in the study 
 
Recommendation 1 
Biologic therapies are recommended as options for 
treatment of adults with the following characteristics: 
A. Active RA as measured by DAS 28 ≥ 3.2 
B. Have undergone trial of two DMARDS including 
methotrexate (unless contraindicated). A trial being 
defined as at least two DMARDs usually given 
concurrently over a 6 month period with 2 months at 
standard doses 
 
 
Figure 2: Number of patients who had DAS 28 
performed before starting treatment 
 
Results: 
Of the 22 patients included in the audit, 11 
patients had a DAS 28 performed prior to starting 
biologic therapy.  
 
All 11 patients had DAS scores >3.2  
Initial control of disease activity with at least two 
DMARDS at standard doses was seen in 91% of 
patients. 
 
Recommendation 2 
Treatment should be continued if there is an 
adequate response to treatment following the first 6 
months of continuous treatment. An adequate 
response is defined as a good or moderate EULAR 
response. 
Results: 
Four patients had a DAS 28 score performed 
within 3 to 9 months of starting treatment. Of these 4 
patients only 2 patients had a DAS 28 performed 
before starting treatment. Thus the EULAR response 
criteria could only be measured in the latter 2 patients. 
Both patients had a moderate EULAR response 
(Figure 3). 
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Figure 3 - The EULAR response criteria 
5 
 
Recommendation 3 
After initial response, anti TNF treatment in RA 
should be monitored with assessment of DAS 28 no less 
frequently than 6 monthly. Anti TNF therapy should 
be withdrawn if an inadequate response is seen despite 
6 months of continuous therapy 
Results: 
Of the 22 patients suffering from RA who were 
started on biologic agents only 2 patients had continuous 
monitoring as recommended (Figure 4).  
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Number of patients who had continuous DAS 28 
monitoring during treatment 
 
Discussion 
Biologic drugs represent an exciting advance in the 
treatment of RA. The response to biologics is not uniform 
or universal. Generally 20% of patients experience a 60% 
improvement in DAS28 while 60% of patients will 
experience a 20% improvement in the same score. Some 
patients fail to respond altogether and early recognition of 
these patients is important as these drugs are very 
expensive (approximately 10,000 euro per patient per year) 
and have potentially serious side effects particularly 
infection. Treatment of patients who respond to treatment 
is long term so the cost is ongoing. These drugs are an 
important resource which has to be used appropriately, 
judiciously and effectively.  
Use of the DAS 28 to commence, change or stop 
biologic therapies in RA is to a degree controversial. 
While we have no better gold standard at present, there is 
concern that DAS 28 fails to measure metatarsophalangeal 
joint involvement given that these joints are commonly 
involved in the disease process. Also, the subjective 
criterion (patient well-being) and joint tenderness (by 
perhaps applying firmer pressure to the joints) can 
greatly skew the result obtained. Therefore intra- and 
inter-reliability of measurement can be significant. 
In contrast to the BSRBG recommendations on 
eligibility criteria for first biologic which include a 
DAS 28 score ≥3.2, the National Institute of Health 
and Clinical Excellence (NICE) have an entry level for 
biologic therapy in RA of 5.1. The BSRBG suggest 
that this is an arbitrary level which is driven by 
economics rather than purely patient needs. The group 
argues that a patient with a DAS28 of, for example, 
4.8, is just as likely to have disease progression but 
would not be eligible for biologic therapy. 
It is clear from this audit that we are not adhering 
to the above recommendations in our Department.  
Some reasons for this include:  
1. DAS 28 calculator not readily available at  
out-patients; 
2. The high turnover of staff in the department -  
doctors working in the department for only a few 
months are not adequately trained to perform 
DAS 28 scores. 
3. Few of the permanent staff have had formal 
training in DAS 28 measurement techniques to 
reduce intra- and inter- observer variability. 
4. Time constraints including difficulty in 
scheduling appointments in line with 
recommendations (at least 6 monthly intervals). 
Current first available follow up appointments for 
most of the consultants is greater than 6 months. 
 
Recommendations following audit 
1. A proforma is being developed to ensure that all 
RA patients have a baseline DAS score and prior 
non biologic DMARD history recorded prior to 
commencement of biologic therapies. 
2. Plans are in hand for a biologic clinic to be set up 
to allow better scheduling of appointments for 
patients on biologics and improve detection of 
potential adverse reactions. This will complement 
the imminent commencement of an early arthritis 
clinic for detection of persistent inflammatory 
arthritis. 
3. Training of all staff in the Department caring for 
patients on biologics to standardize performance 
of the DAS 28 and consequently minimize inter- 
and intra- observer variation. 
4. Regular review of patients on biologic therapies 
to identify patients who have an inadequate 
response to biologics according to BSR and 
EULAR criteria. In these patients switching of a 
 DAS-28 
Change in 
DAS-28 
>5.1 ≤ 5.1 and 
>3.2 
≤3.2 
>1.2 Moderate Moderate Good 
>0.6 and 
≤1.2 
None Moderate Moderate 
≤ 0.6 None None None 
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biologic or withdrawal of biologic would lead to more 
effective and efficient use of resources. 
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